Azitra, Inc. AZTR
Azitra, Inc. (NYSE: AZTR) is a dermatology drug developer. Its lead program, ATR-04, is in Phase 1 for EGFR-inhibitor-associated papulopustular rash in cancer patients. Its next catalyst on record is ATR-COSF: Cosmetic study in human participants (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ATR-COSF — Cosmetic study in human participants (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ATR-04 | EGFRi-associated rash | biologic-other | Phase 1 |
| ATR-12 | Netherton syndrome | biologic-other | Phase 1 |
| ATR-01 | Ichthyosis vulgaris | biologic-other | Pre-clinical |
| ATR-COSF | Cosmetic ingredient (fine lines and wrinkles) | protein/peptide | NA_NON_THERAPEUTIC |
Recent results and decisions
- Oct 29, 2026n/a Azitra expands Phase 1/2 trial of ATR-04 to include patients with rashes from KRAS and MEK inhibitors, including neurofibromatosis type 1 patients.
The multicenter, randomized, double-blind, vehicle-controlled Phase 1/2 study (NCT06830863) is evaluating the safety, tolerability, bioavailability, pharmacodynamics, and preliminary efficacy of topical ATR04-484.
Filing - Oct 29, 2026positive Safety review committee recommended proceeding to Cohort 2 of ATR-04 Phase 1/2 trial following review of Cohort 1 safety data.
The protocol amendments for the Phase 1/2 clinical trial follow Azitra's recent announcement that the study's safety review committee recommended proceeding to Cohort 2 following its review of available safety data from Cohort 1.
Filing - Oct 29, 2026positive Safety review committee recommended proceeding to Cohort 2 of ATR-04 Phase 1/2 trial following review of Cohort 1 safety data.
The protocol amendments for the Phase 1/2 clinical trial follow Azitra's recent announcement that the study's safety review committee recommended proceeding to Cohort 2 following its review of available safety data from Cohort 1.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.